MicroRNAs in the failing heart--novel therapeutic targets?
Heart failure is a common and disabling disease with high mortality that carries substantial societal costs. Current therapeutic strategies are aimed at relieving symptoms, avoiding hospitalization, and prolonging life, but disease progression is ultimately inevitable. MicroRNAs (miRNAs) are short, non-coding RNA molecules with pervasive roles in eukaryotic biology, annealing to complimentary sites on target mRNAs, and repressing gene expression. The fact that miRNAs are dysregulated in many human disorders, including cardiovascular disease, and the relative ease with which endogenous miRNA expression can be altered using synthetic antisense oligos has stirred enthusiasm for these molecules as potential drug targets. The aim of this review article was to summarize the current knowledge on the roles of miRNA in the pathophysiology of heart failure as well as the use of miRNAs as therapeutic targets and diagnostic tools for the disease.
Department of Cardiology, Clinical Sciences, Lund University , Lund , Sweden.
Olof
O
Gidlöf
David
D
Erlinge
D000818:Animals; D005819:Genetic Markers; D015316:Genetic Therapy / Q000379:methods / Q000639:trends; D006333:Heart Failure / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism; D009200:Myocardial Contraction / Q000235:genetics; D012323:RNA Processing, Post-Transcriptional / Q000187:drug effects*
D005819:Genetic Markers; D035683:MicroRNAs
Therapeutic targets; diagnostic biomarkers; heart failure; microRNA; review